Management of cognitive and negative symptoms in schizophrenia-Reference-Cited by-同舟云学术

Management of cognitive and negative symptoms in schizophrenia

Published:2022-10-01 Issue:5 Volume:12 Page:282-299
ISSN:2168-9709
Container-title:Mental Health Clinician
language:en
Short-container-title:

Author:

Maroney Megan¹^ORCID

Affiliation:

1. 1 (Corresponding author) Clinical Associate Professor, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey; Clinical Psychiatric Pharmacist, Monmouth Medical Center, Long Branch, New Jersey, meganemaroney@gmail.com

Abstract

Abstract Currently available antipsychotics provide only modest benefit in managing the cognitive and negative symptoms of schizophrenia even though these symptoms are often the most impairing in patients' daily lives. Certain antipsychotics may have slight benefits over others, and several nonpharmacologic and pharmacologic adjunctive treatments have been evaluated in recent clinical trials. Recently published meta-analyses and clinical studies of such treatments are reviewed. Potential strategies to manage cognitive and negative symptoms, including deprescribing of medications that may exacerbate these symptoms, are described using theoretical case examples.

Publisher

College of Psychiatric and Neurologic Pharmacists (CPNP)

Subject

Pharmacology (medical),Neurology (clinical),General Pharmacology, Toxicology and Pharmaceutics,Neuropsychology and Physiological Psychology

Link

https://meridian.allenpress.com/mhc/article-pdf/12/5/282/3139035/i2168-9709-12-5-282.pdf

Reference92 articles.

1. Carbon M, Correll CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014; 19Suppl 1: 38- 52; quiz 35-7, 53. DOI: 10.1017/S1092852914000601. PubMed PMID: 25403863.

2. Galderisi S, Mucci A, Dollfus S, Nordentoft M, Falkai P, Kaiser S, et al. EPA guidance on assessment of negative symptoms in schizophrenia. Eur Psychiatr. 2021; 64(1): e23. DOI: 10.1192/j.eurpsy.2021.11. PubMed PMID: 33597064; PubMed Central PMCID: PMC8080207.

3. Fleischhacker WW, Podhorna J, Gröschl M, Hake S, Zhao Y, Huang S, et al. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. Lancet Psychiatry. 2021; 8(3): 191- 201. DOI: 10.1016/S2215-0366(20)30513-7.

4. Davidson M, Saoud J, Staner C, Noel N, Werner S, Luthringer E, et al. Efficacy and safety of roluperidone for the treatment of negative symptoms of schizophrenia. Schizophr Bull. 2022; 48(3): 609- 19. DOI: 10.1093/schbul/sbac013. PubMed PMID: 35211743; PubMed Central PMCID: PMC9077422.

5. Bugarski-Kirola D, Arango C, Fava M, Nasrallah H, Liu I-Y, Abbs B, et al. Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe. Lancet Psychiatry. 2022; 9: 46- 58. DOI: 10.1016/ S2215-0366(21)00386-2.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical decision-making before discharge in hospitalized persons with schizophrenia: a Spanish Delphi expert consensus;Frontiers in Psychiatry;2024-06-10

2. Navigating Schizophrenia Treatment: Balancing Symptom Relief and Long-Term Needs;New Approaches to the Management and Diagnosis of Schizophrenia [Working Title];2024-05-29

3. Pharmacological Treatment of Cognitive Impairment Associated With Schizophrenia: State of the Art and Future Perspectives;Schizophrenia Bulletin Open;2024-01-01

4. Editorial: Innovative treatments for neuro-psychiatric diseases;Frontiers in Neuroscience;2023-07-07